

## 제 14 장

# 호르몬요법의 금기증

1. Baber RJ, Panay N, Fenton A; IMS Writing Group. IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric* 2016; 19: 109-150.
2. Blondon M, Wiggins KL, Van Hylckama Vlieg A, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study. *Br J Haematol* 2013; 163: 418-420.
3. Committee of Clinical Practice Guideline of the Korean Society of Lipid and Atherosclerosis (KSoLA). Korean Guidelines for the Management of Dyslipidemia 4th ed. 2018 <http://www.lipid.or.kr>
4. Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* 2015; 100: 4012-4020.
5. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. *Maturitas* 2004; 49: 189-203.
6. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause* 2017; 24: 728-753.
7. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ* 2019; 364: k4810.
8. Racine A, Bijon A, Fournier A, et al. Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. *CMAJ* 2013;185:555-561.
9. The 2017 hormone therapy position statement of The North American Menopause Society.
10. Liu B. Is transermal menopausal hormone therapy a safer option than oral therapy? *CMAJ* 2013; 16: 549-550.
11. Pavlovic JM. Evaluation and management of migraine in midlife women. *Menopause* 2018;25: 927-9.
12. Allais G, Chiarle G, Sinigaglia S, et al. Estrogen, migraine, and vascular risk. *Neurol Sci* 2018;39(supple 1): 11-20.
13. Broner SW, Bobker S, Klebanoff L. Migraine in women. *Semin Neurol* 2017;37:601-610.

14. Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systemic review. *Int J Women's Health* 2015;7:773-782
15. Cheung KL, Stefanick ML, Allison MA, et al. Menopausal symptoms in women with chronic kidney disease. *Menopause* 2015;22:1006-1011.
16. Vellanki K, Hou S. Menopuase in CKD. *Am J Kidney Dis* 2018;71:710-719.
17. Pietrzak B, Cyganek A, Jabiry-Zieniewicz Z, et al. Safety and efficacy of hormonal therapy in menopausal kidney-allograft recipients. *Transplant Proc* 2006;38:184-187.
18. Strippoli GFM; for the Collaborative Dperession and Sexual Dysfunction in women with ESRD requiring hemodialysis. *Clin Am Soc Nephrol* 2012;7:974-981.
19. Soared CN. Depression and menopause. An update on currnet knowledge and clinical management for this critical window. *Med Clin N Am* 2019;103:651-667.
20. Bromberger JT, Kravitz HM. Youk A, et al. Patterns of depressive disorders across 13 years and their determinants among midlife women: SWAN mental health study. *J Affect Disord* 2016;206:31-40.
21. Rubinow DR, Johnson SL, Schmidt PF, et al. Efficacy of estradiol in perimenopausal depression: so much promise and so few answers. *Depress Anxiety* 2015;32:539-49.
22. Srivastava DP, Woolfrey KM, Evans PD. Mechanisms underlying the interactions between rapid estrogenic and B-올 control of synaptic connectivity. *Neuroscience* 2013;239:17-33.
23. The 2017 hormone therapy position statement of The North American Menopause Society.
24. Vagelli R, Tani C, Mosca M. Pregnancy and menopause in patinets with systemic lupus erythematosus and/or antiphospholipid syndrome. *Pol Arch Intern Med* 2017;127:115-121.
25. Bove R. Autoimmune diseases and reproductive aging. *Clin Immuno*.